Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 4Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 10Myeloid 3Sarcoma 1Head & Neck 1Genitourinary 1

Conditions

Osteosarcoma 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Magnetic Resonance Spectroscopy 15Surgical Procedures, Operative 14Radiotherapy 13Blood Specimen Collection 13Biopsy 13atezolizumab 12Gemcitabine 12fludarabine 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 7liposomal doxorubicin 5abemaciclib 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × merphos × Sarcoma × Clear all
NCT05691478 2026-06-03

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡